

Livio Pagano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1575276/publications.pdf>

Version: 2024-02-01

403
papers

21,217
citations

12330

69
h-index

12272

133
g-index

463
all docs

463
docs citations

463
times ranked

17435
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	3.5	15
2	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	5.2	46
3	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. <i>Blood</i> , 2022, 139, 1588-1592.	1.4	70
4	THE TREATMENT OF ADVANCED-STAGE MYCOSIS FUNGOIDES AND SEZARY SYNDROME: A HEMATOLOGIST'S POINT OF VIEW.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022029.	1.3	2
5	When Viruses Meet Fungi: Tackling the Enemies in Hematology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 184.	3.5	0
6	A High-Risk Profile for Invasive Fungal Infections Is Associated with Altered Nasal Microbiota and Niche Determinants. <i>Infection and Immunity</i> , 2022, 90, e0004822.	2.2	6
7	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	7.2	19
8	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	7.2	63
9	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	5.2	8
10	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel)</i> , 2022, 8, 1063-1077.	10.6	10
11	Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	39
12	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	8
13	In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome. <i>Platelets</i> , 2021, 32, 378-382.	2.3	2
14	Do high MICs predict the outcome in invasive fusariosis?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1063-1069.	3.0	28
15	Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. <i>British Journal of Haematology</i> , 2021, 193, 316-324.	2.5	12
16	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	4.4	4
17	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. <i>Chemotherapy</i> , 2021, 66, 47-52.	1.6	10
18	<i>Pneumocystis jirovecii</i> Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, S114-S120.	5.8	50

#	ARTICLE	IF	CITATIONS
19	The important role of intensive induction chemotherapy in the treatment of acute myeloid leukemia. Expert Review of Hematology, 2021, 14, 303-314.	2.2	4
20	EXTRAMEDULLARY INVOLVEMENT IN ACUTE MYELOID LEUKEMIA. A SINGLE CENTER TEN YEARS EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021030.	1.3	15
21	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. HemaSphere, 2021, 5, e612.	2.7	29
22	Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience. Frontiers in Oncology, 2021, 11, 614721.	2.8	6
23	Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic Patients. Infection and Immunity, 2021, 89, e0010521.	2.2	12
24	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
25	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infectious Diseases, The, 2021, 21, e375-e386.	9.1	80
26	Disseminated Geosmithia argillacea Infection in a Patient with Ph-Positive Acute Lymphoblastic Leukemia. Case Report and Literature Review. Journal of Fungi (Basel, Switzerland), 2021, 7, 778.	3.5	1
27	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. Journal of Fungi (Basel, Switzerland), 2021, 7, 4.	3.5	5
28	Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey. Blood Advances, 2021, 5, 5608-5611.	5.2	11
29	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
30	Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin. Blood, 2021, 138, 4381-4381.	1.4	1
31	Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath?. Acta Haematologica, 2020, 143, 91-92.	1.4	0
32	Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT. Annals of Hematology, 2020, 99, 207-209.	1.8	1
33	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
34	Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review. European Journal of Haematology, 2020, 104, 148-150.	2.2	6
35	Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Advances, 2020, 4, 4838-4848.	5.2	44
36	Isavuconazole Animal Data and Clinical Data. Journal of Fungi (Basel, Switzerland), 2020, 6, 209.	3.5	7

#	ARTICLE	IF	CITATIONS
37	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.	6.2	28
38	Reducing infectious complications after allogeneic stem cell transplant. <i>Expert Review of Hematology</i> , 2020, 13, 1235-1251.	2.2	4
39	Reply to Luppi et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 3266-3266.	5.8	0
40	Developments in identifying and managing mucormycosis in hematologic cancer patients. <i>Expert Review of Hematology</i> , 2020, 13, 895-905.	2.2	6
41	Prospective multicentre study on azole resistance in <i>Aspergillus</i> isolates from surveillance cultures in haematological patients in Italy. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 231-237.	2.2	6
42	Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium. <i>Blood Cancer Journal</i> , 2020, 10, 75.	6.2	2
43	Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study). <i>Mycoses</i> , 2020, 63, 1094-1100.	4.0	6
44	Comparative performance evaluation of Wako β -glucan test and Fungitell assay for the diagnosis of invasive fungal diseases. <i>PLoS ONE</i> , 2020, 15, e0236095.	2.5	20
45	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
46	Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis. <i>Mycoses</i> , 2020, 63, 900-910.	4.0	10
47	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 36.	3.5	15
48	Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3002-3005.	1.3	4
49	Voriconazole plus terbinafine combination antifungal therapy for invasive <i>Lomentospora prolificans</i> infections: analysis of 41 patients from the FungiScope [®] registry 2008-2019. <i>Clinical Microbiology and Infection</i> , 2020, 26, 784.e1-784.e5.	6.0	47
50	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope [®] registry. <i>Mycoses</i> , 2020, 63, 437-442.	4.0	41
51	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP [®] EBMT, EORTC [®] IG and SEIFEM survey. <i>Mycoses</i> , 2020, 63, 420-429.	4.0	7
52	Frequently asked questions regarding SARS-CoV-2 in cancer patientsâ€”recommendations for clinicians caring for patients with malignant diseases. <i>Leukemia</i> , 2020, 34, 1487-1494.	7.2	50
53	Polymorphisms within the <i>ARNT2</i> and <i>CX3CR1</i> Genes Are Associated with the Risk of Developing Invasive Aspergillosis. <i>Infection and Immunity</i> , 2020, 88, .	2.2	8
54	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020, 136, 32-33.	1.4	1

#	ARTICLE	IF	CITATIONS
55	A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group. <i>American Journal of Hematology</i> , 2019, 94, 1104-1112.	4.1	19
56	The economic impact of biosimilars in Italy: a scenario analysis. <i>Global & Regional Health Technology Assessment</i> , 2019, 2019, 228424031985802.	0.1	0
57	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
58	Bloodstream infections caused by <i>Escherichia coli</i> in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. <i>PLoS ONE</i> , 2019, 14, e0224465.	2.5	27
59	Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience. <i>Hematological Oncology</i> , 2019, 37, 496-497.	1.7	1
60	Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. <i>Medical Mycology</i> , 2019, 57, S127-S137.	0.7	14
61	Fungaemia in haematological malignancies: SEIFEM 2015 survey. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13083.	3.4	20
62	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 116.	3.5	12
63	Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases. <i>Mycoses</i> , 2019, 62, 252-260.	4.0	54
64	Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	3.0	11
65	Rhodotorula infection in haematological patient: Risk factors and outcome. <i>Mycoses</i> , 2019, 62, 223-229.	4.0	17
66	Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid. <i>Leukemia and Lymphoma</i> , 2019, 60, 1328-1330.	1.3	2
67	Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study. <i>HemaSphere</i> , 2019, 3, e320.	2.7	8
68	Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients. <i>Blood</i> , 2019, 134, 1363-1363.	1.4	2
69	PS1437 SETD2-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS. <i>HemaSphere</i> , 2019, 3, 662-663.	2.7	0
70	In Systemic Mastocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 4204-4204.	1.4	0
71	ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 12-21.	3.0	91
72	Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. <i>Journal of Clinical Immunology</i> , 2018, 38, 7-9.	3.8	2

#	ARTICLE	IF	CITATIONS
73	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018, 97, 791-798.	1.8	10
74	SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders. <i>Expert Review of Hematology</i> , 2018, 11, 155-168.	2.2	4
75	Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. <i>Annals of Hematology</i> , 2018, 97, 1717-1726.	1.8	72
76	Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. <i>Clinical Microbiology and Infection</i> , 2018, 24, e1-e38.	6.0	942
77	Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1,3- β -D-glucan antigenemia and multiphasic contrast-enhanced computed tomography. <i>Supportive Care in Cancer</i> , 2018, 26, 1691-1694.	2.2	3
78	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. <i>Leukemia</i> , 2018, 32, 139-148.	7.2	28
79	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. <i>Journal of Infection</i> , 2018, 76, 20-37.	3.3	125
80	Estimated burden of fungal infections in Italy. <i>Journal of Infection</i> , 2018, 76, 103-106.	3.3	11
81	Mastocytosis: One Word for Different Diseases. <i>Oncology and Therapy</i> , 2018, 6, 129-140.	2.6	2
82	INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018063.	1.3	14
83	Therapy-related myeloid neoplasms: clinical perspectives. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5909-5915.	2.0	12
84	Invasive Mold Infections in Patients with Chronic Lymphoproliferative Disorders. <i>Current Fungal Infection Reports</i> , 2018, 12, 179-186.	2.6	1
85	Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 531-542.	4.4	6
86	Invasive fungal infections in high-risk patients: report from TIMM-8 2017. <i>Future Science OA</i> , 2018, 4, FSO307.	1.9	28
87	Isavuconazole in Hematological Patients: Results of a Real-Life Multicenter Seifem Study. <i>Blood</i> , 2018, 132, 3710-3710.	1.4	1
88	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. <i>Blood</i> , 2018, 132, 4078-4078.	1.4	1
89	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	1.4	3
90	Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience. <i>Blood</i> , 2018, 132, 5552-5552.	1.4	1

#	ARTICLE	IF	CITATIONS
91	MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. <i>Blood</i> , 2018, 132, 1779-1779.	1.4	1
92	Invasive infections due to <i>Saprochaete</i> and <i>Geotrichum</i> species: Report of 23 cases from the FungiScope Registry. <i>Mycoses</i> , 2017, 60, 273-279.	4.0	78
93	Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. <i>Haematologica</i> , 2017, 102, e108-e111.	3.5	37
94	Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?. <i>Medical Mycology</i> , 2017, 55, 82-86.	0.7	43
95	Improved Detection of Minimal Residual Disease by 11C-Methionine PET/CT in a Young Patient With Unusual Extramedullary Presentation of Recurrent Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e130-e134.	1.3	5
96	SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2859-2864.	1.3	6
97	<i>Pneumocystis jirovecii</i> pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipientsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw580.	3.0	13
98	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2359-2367.	3.0	65
99	Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. <i>Journal of Chemotherapy</i> , 2017, 29, 131-143.	1.5	26
100	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. <i>Haematologica</i> , 2017, 102, 433-444.	3.5	468
101	Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey. <i>Leukemia Research</i> , 2017, 53, 74-81.	0.8	37
102	Hyperleukocytosis and leukostasis: management of a medical emergency. <i>Expert Review of Hematology</i> , 2017, 10, 147-154.	2.2	49
103	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. <i>Haematologica</i> , 2017, 102, e407-e410.	3.5	17
104	Granulocyte Transfusions: A Critical Reappraisal. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2034-2041.	2.0	20
105	Reply to the letter to the editor â€œchronic disseminated candidiasisâ€ by Kenneth Rolston. <i>Supportive Care in Cancer</i> , 2017, 25, 1045-1046.	2.2	0
106	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29.	5.7	98
107	INFECTIONS IN MYELOYDYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, e2018039.	1.3	14
108	Antifungal therapy in hematopoietic stem cell transplant recipients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, e2016039.	1.3	12

#	ARTICLE	IF	CITATIONS
109	Defining invasive fungal infection risk in hematological malignancies: a new tool for clinical practice. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017012.	1.3	7
110	Common Genetic Polymorphisms within NF κ B-Related Genes and the Risk of Developing Invasive Aspergillosis. <i>Frontiers in Microbiology</i> , 2016, 7, 1243.	3.5	13
111	Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. <i>British Journal of Haematology</i> , 2016, 174, 188-202.	2.5	148
112	A cluster of <i>Geotrichum clavatum</i> (<i>Saprochaete clavata</i>) infection in haematological patients: a first Italian report and review of literature. <i>Mycoses</i> , 2016, 59, 594-601.	4.0	44
113	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351.	2.2	31
114	Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. <i>BMC Infectious Diseases</i> , 2016, 16, 667.	2.9	109
115	Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry. <i>Supportive Care in Cancer</i> , 2016, 24, 3839-3845.	2.2	16
116	Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2214-2219.	2.0	13
117	Bloodstream infections caused by <i>Klebsiella pneumoniae</i> in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. <i>American Journal of Hematology</i> , 2016, 91, 1076-1081.	4.1	115
118	ECIL guidelines for treatment of <i>Pneumocystis jirovecii</i> pneumonia in non-HIV-infected haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2405-2413.	3.0	141
119	ECIL guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2397-2404.	3.0	211
120	Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOMics Consortium. <i>Infection and Immunity</i> , 2016, 84, 643-657.	2.2	35
121	Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. <i>Expert Review of Hematology</i> , 2016, 9, 197-208.	2.2	33
122	A T cell lymphoblastic lymphoma with mucormycosis as unusual etiology of acute cerebral ischemia. <i>Annals of Hematology</i> , 2016, 95, 517-518.	1.8	4
123	Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia. <i>PLoS ONE</i> , 2016, 11, e0159569.	2.5	21
124	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study. <i>Blood</i> , 2016, 128, 3700-3700.	1.4	0
125	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 3136-3136.	1.4	1
126	Retrospective Chart Review of Hospitalisations During Chemotherapy for Adult Patients with Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) In Italy. <i>Value in Health</i> , 2015, 18, A443.	0.3	4

#	ARTICLE	IF	CITATIONS
127	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <sc>SEIFEM</sc> registry. British Journal of Haematology, 2015, 170, 434-439.	2.5	14
128	Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Annals of Hepatology, 2015, 14, 168-174.	1.5	15
129	Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. Journal of Chemotherapy, 2015, 27, 1-12.	1.5	19
130	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica, 2015, 100, 284-292.	3.5	64
131	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the <sc>Italian network on secondary leukemias</sc>. American Journal of Hematology, 2015, 90, E80-5.	4.1	93
132	Reviewing the importance and evolution of fungal infections and potential antifungal resistance in haematological patients. Journal of Global Antimicrobial Resistance, 2015, 3, 237-241.	2.2	11
133	Rapid response of nodular <sc>CD</sc>30-positive mycosis fungoides to brentuximab vedotin. British Journal of Haematology, 2015, 168, 617-617.	2.5	9
134	Reply to Wong et al. Clinical Infectious Diseases, 2015, 61, 1352-1352.	5.8	1
135	Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clinical Microbiology and Infection, 2015, 21, 337-343.	6.0	172
136	Systemic mastocytosis mimicking carcinoid syndrome. Endocrine, 2015, 48, 718-719.	2.3	2
137	Bloodstream Infections Caused By Klebsiella Pneumoniae in Onco-Hematological Patients: Incidence and Clinical Impact of Carbapenem Resistance in a Multicentre Prospective Survey. Blood, 2015, 126, 3757-3757.	1.4	3
138	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. Blood, 2015, 126, 4085-4085.	1.4	2
139	Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene. , 2015, , .		0
140	Granulocyte Transfusions at Appropriate Doses Improve Survival in Hematological Patients with Febrile Neutropenia. Blood, 2015, 126, 3566-3566.	1.4	0
141	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. Blood, 2015, 126, 1023-1023.	1.4	0
142	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. Blood, 2015, 126, 4887-4887.	1.4	1
143	Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Annals of Hepatology, 2015, 14, 168-74.	1.5	7
144	Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses, 2014, 57, 342-350.	4.0	43

#	ARTICLE	IF	CITATIONS
145	Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2014, 370, 421-432.	27.0	265
146	Carbapenemase-producing <i>Klebsiella pneumoniae</i> and Hematologic Malignancies. <i>Emerging Infectious Diseases</i> , 2014, 20, 1235-1236.	4.3	48
147	SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. <i>Infection</i> , 2014, 42, 141-151.	4.7	59
148	Improvement in the outcome of invasive fusariosis in the last decade. <i>Clinical Microbiology and Infection</i> , 2014, 20, 580-585.	6.0	151
149	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: <i>Fusarium</i> spp., <i>Scedosporium</i> spp. and others. <i>Clinical Microbiology and Infection</i> , 2014, 20, 27-46.	6.0	383
150	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014, 20, 47-75.	6.0	262
151	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014, 20, 5-26.	6.0	547
152	The role of primary antifungal prophylaxis in patients with haematological malignancies. <i>Clinical Microbiology and Infection</i> , 2014, 20, 19-26.	6.0	20
153	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. <i>Clinical Microbiology and Infection</i> , 2014, 20, 76-98.	6.0	400
154	SP-033 ANTIFUNGAL TREATMENTS IN FEBRILE NEUTROPENIA: FROM SCIENTIFIC TRIALS TO CLINICAL PRACTICE. <i>Leukemia Research</i> , 2014, 38, S17.	0.8	0
155	Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF- κ B pathway inhibition. <i>Leukemia</i> , 2014, 28, 1606-1616.	7.2	164
156	Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3142-3147.	3.0	21
157	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
158	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1080-1088.	2.0	54
159	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 1881-1881.	1.4	2
160	Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2014, 124, 3880-3880.	1.4	9
161	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. <i>Blood</i> , 2014, 124, 1856-1856.	1.4	0
162	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014, 124, 3265-3265.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Invasive Fungal Infections in Acute Promyelocytic Leukemia Patients. Results of a Prospective Multicenter Study in Italy. <i>Blood</i> , 2014, 124, 3682-3682.	1.4	0
164	A prospective, multicentre survey on antifungal therapy in neutropenic paediatric haematology patients. <i>Mycoses</i> , 2013, 56, 21-25.	4.0	3
165	<i>Nocardia</i> spp infections among hematological patients: results of a retrospective multicenter study. <i>International Journal of Infectious Diseases</i> , 2013, 17, e610-e614.	3.3	39
166	Hema e-Chart Registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. <i>Clinical Microbiology and Infection</i> , 2013, 19, 757-762.	6.0	27
167	Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarism. <i>Growth Hormone and IGF Research</i> , 2013, 23, 109-113.	1.1	24
168	A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. <i>Hematological Oncology</i> , 2013, 31, 117-126.	1.7	21
169	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. <i>Haematologica</i> , 2013, 98, e127-e130.	3.5	99
170	Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). <i>Haematologica</i> , 2013, 98, 492-504.	3.5	282
171	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. <i>Haematologica</i> , 2013, 98, 239-246.	3.5	268
172	Reply to "A combination treatment approach and cord blood stem cell transplant for blastic plasmacytoid dendritic cell neoplasm" and to "A low-grade B-cell lymphoma with polymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement" <i>Dendritic cell leukemia</i> . <i>Haematologica</i> , 2013, 98, e37-e37.	3.5	2
173	Characterization of Specific Immune Responses to Different <i>Aspergillus</i> Antigens during the Course of Invasive Aspergillosis in Hematologic Patients. <i>PLoS ONE</i> , 2013, 8, e74326.	2.5	48
174	Molecular Profiling Of Blastic Plasmacytoid Dendritic CELL Neoplasm Reveals A Unique Pattern and Suggests Selective Sensitivity To NF-KB Pathway Inhibition. <i>Blood</i> , 2013, 122, 2502-2502.	1.4	3
175	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. <i>Blood</i> , 2013, 122, 2145-2145.	1.4	0
176	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. <i>Blood</i> , 2013, 122, 2659-2659.	1.4	0
177	Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012040.	1.3	8
178	First case of breakthrough pneumonia due to <i>Aspergillus nomius</i> in a patient with acute myeloid leukemia. <i>Medical Mycology</i> , 2012, 50, 746-750.	0.7	9
179	Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. <i>Annals of Oncology</i> , 2012, 23, 1499-1502.	1.2	68
180	Risks for infection in patients with myelodysplasia and acute leukemia. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 612-618.	3.1	25

#	ARTICLE	IF	CITATIONS
181	The management of febrile neutropenia in the posaconazole era: a new challenge?. <i>Haematologica</i> , 2012, 97, 963-965.	3.5	14
182	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44.	17.0	49
183	Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry. <i>Clinical Infectious Diseases</i> , 2012, 55, 1515-1521.	5.8	77
184	A prospective survey of febrile events in hematological malignancies. <i>Annals of Hematology</i> , 2012, 91, 767-774.	1.8	48
185	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML107). <i>British Journal of Haematology</i> , 2012, 156, 205-212.	2.5	65
186	Primary plasma cell leukemia in the era of new drugs: Has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 141-149.	4.4	18
187	Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule. <i>Leukemia Research</i> , 2012, 36, e15-e17.	0.8	3
188	Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 331-333.	0.8	28
189	Derivation and Validation of a Scoring System to Identify Patients with Bacteremia and Hematological Malignancies at Higher Risk for Mortality. <i>PLoS ONE</i> , 2012, 7, e51612.	2.5	18
190	Uncommon yeast infections in hematological patients: from diagnosis to treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1067-1075.	4.4	18
191	Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 881-892.	4.4	11
192	5-Azacitidine in chronic myelomonocytic leukemia: case report and review of literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011011.	1.3	5
193	The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. <i>Haematologica</i> , 2011, 96, 1366-1370.	3.5	56
194	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1859-1867.	6.0	566
195	Update on invasive fungal disease. <i>Future Microbiology</i> , 2011, 6, 985-989.	2.0	6
196	Primary plasma cell leukemia followed by testicular plasmacytoma. <i>International Journal of Hematology</i> , 2011, 93, 224-227.	1.6	7
197	Etiology of Febrile Episodes in Patients With Acute Myeloid Leukemia: Results From the Hema e-Chart Registry. <i>Archives of Internal Medicine</i> , 2011, 171, 1502.	3.8	27
198	Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. <i>Medical Mycology</i> , 2011, 49, S13-S16.	0.7	13

#	ARTICLE	IF	CITATIONS
199	Multidrug resistant <i>Pseudomonas aeruginosa</i> bloodstream infection in adult patients with hematologic malignancies. <i>Haematologica</i> , 2011, 96, e1-e3.	3.5	67
200	Diagnosis of Invasive Aspergillosis by a Commercial Real-Time PCR Assay for <i>Aspergillus</i> DNA in Bronchoalveolar Lavage Fluid Samples from High-Risk Patients Compared to a Galactomannan Enzyme Immunoassay. <i>Journal of Clinical Microbiology</i> , 2011, 49, 4273-4278.	3.9	114
201	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. <i>Annals of Oncology</i> , 2011, 22, 1628-1635.	1.2	65
202	Treatment Strategies for Invasive Aspergillosis in Neutropenic Patients: Voriconazole or Liposomal Amphotericin-B?. <i>Journal of Chemotherapy</i> , 2011, 23, 5-8.	1.5	12
203	Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, i5-i14.	3.0	178
204	INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011069.	1.3	24
205	SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011052.	1.3	8
206	Epigenetic changes in therapy-related MDS/AML. <i>Chemico-Biological Interactions</i> , 2010, 184, 46-49.	4.0	36
207	Incidence and susceptibility to therapy-related myeloid neoplasms. <i>Chemico-Biological Interactions</i> , 2010, 184, 39-45.	4.0	85
208	Current therapeutic approaches to fungal infections in immunocompromised hematological patients. <i>Blood Reviews</i> , 2010, 24, 51-61.	5.7	47
209	Caspofungin for the treatment of candidaemia in patients with haematological malignancies. <i>Clinical Microbiology and Infection</i> , 2010, 16, 298-301.	6.0	6
210	Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies. <i>Mycoses</i> , 2010, 53, 89-92.	4.0	8
211	Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2013-2018.	3.0	19
212	Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. <i>Bone Marrow Transplantation</i> , 2010, 45, 1668-1670.	2.4	14
213	Soil and vegetable crop response to addition of different levels of municipal waste compost under Mediterranean greenhouse conditions. <i>Agronomy for Sustainable Development</i> , 2010, 30, 701-709.	5.3	43
214	Hema e-Chart: Italian Registry for Prospective Analysis of Epidemiology, Management and Outcome of Febrile Events in Patients with Hematological Malignancies. <i>Journal of Chemotherapy</i> , 2010, 22, 20-24.	1.5	5
215	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 181-185.	1.4	28
216	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273

#	ARTICLE	IF	CITATIONS
217	Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107). <i>Blood</i> , 2010, 116, 510-510.	1.4	2
218	Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 322-329.	1.5	79
219	Continuous Surveillance of Invasive Fungal Infection: A Realistic Goal for the Near Future. <i>Clinical Infectious Diseases</i> , 2009, 48, 1801-1801.	5.8	2
220	Molecular Identification and <i>In Vitro</i> Antifungal Susceptibilities of 28 Zygomycetes Isolates: FIMUA-ECMM Survey of Zygomycosis in Italy. <i>Journal of Chemotherapy</i> , 2009, 21, 363-364.	1.5	2
221	A Patient with Acute Myeloid Leukemia and a Solid Mass in the Colon. <i>Clinical Infectious Diseases</i> , 2009, 49, 1897-1898.	5.8	1
222	Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis. <i>American Journal of Hematology</i> , 2009, 84, 381-382.	4.1	42
223	Effect of organic and mineral fertilizers on soil respiration and enzyme activities of two Mediterranean horticultural soils. <i>Biology and Fertility of Soils</i> , 2009, 45, 555-561.	4.3	109
224	ZYGOMYCOSIS: Current approaches to management of patients with haematological malignancies. <i>British Journal of Haematology</i> , 2009, 146, 597-606.	2.5	29
225	Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. <i>Journal of Internal Medicine</i> , 2009, 265, 266-274.	6.0	26
226	The role of neutrophils in the development and outcome of zygomycosis in haematological patients. <i>Clinical Microbiology and Infection</i> , 2009, 15, 33-36.	6.0	33
227	Incidence and clinical impact of extended-spectrum- β -lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009, 58, 299-307.	3.3	144
228	Immature platelet fraction (IPF) in hospitalized patients with neutrophilia and suspected bacterial infection. <i>Journal of Infection</i> , 2009, 59, 201-206.	3.3	27
229	Polymorphisms of detoxification and DNA repair enzymes in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, 1068-1071.	0.8	23
230	Factors associated with mortality in bacteremic patients with hematologic malignancies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 320-326.	1.8	82
231	CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009030.	1.3	8
232	Primary Plasma Cell Leukemia: Results of a Retrospective Italian Multicentric Survey.. <i>Blood</i> , 2009, 114, 2885-2885.	1.4	0
233	Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.. <i>Blood</i> , 2009, 114, 1019-1019.	1.4	0
234	Mast cell leukemia: a report of ten cases. <i>Annals of Hematology</i> , 2008, 87, 505-508.	1.8	41

#	ARTICLE	IF	CITATIONS
235	Combined Voriconazole Plus Caspofungin Therapy for the Treatment of Probable Geotrichum Pneumonia in a Leukemia Patient. <i>Infection</i> , 2008, 36, 65-67.	4.7	24
236	Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>International Journal of Hematology</i> , 2008, 88, 483-488.	1.6	44
237	Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. <i>Hematological Oncology</i> , 2008, 26, 104-107.	1.7	8
238	Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?. <i>European Journal of Haematology</i> , 2008, 81, 242-243.	2.2	38
239	M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. <i>Haematologica</i> , 2008, 93, 1025-1032.	3.5	18
240	Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. <i>Annals of Oncology</i> , 2008, 19, 128-134.	1.2	30
241	Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. <i>Haematologica</i> , 2008, 93, 104-110.	3.5	34
242	Pulmonary aspergillosis in hematologic malignancies: lights and shadows. <i>Haematologica</i> , 2008, 93, 1611-1616.	3.5	5
243	Reliability of Leukostasis Grading Score to Identify High Risk Patients with Hyperleukocytic Leukemia. <i>Blood</i> , 2008, 112, 2979-2979.	1.4	10
244	Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia. <i>Blood</i> , 2008, 112, 2784-2784.	1.4	1
245	Successful Pregnancy in Stage IE Primary Non-Hodgkin's Lymphoma of Uterine Cervix Treated with Neoadjuvant Chemotherapy and Conservative Surgery. <i>Oncology</i> , 2007, 72, 261-264.	1.9	13
246	Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 Study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. <i>Clinical Infectious Diseases</i> , 2007, 45, 1161-1170.	5.8	366
247	Invasive Aspergillosis in Patients with Acute Leukemia: Update on Morbidity and Mortality--SEIFEM-C Report. <i>Clinical Infectious Diseases</i> , 2007, 44, 1524-1525.	5.8	102
248	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007, 109, 3676-3678.	1.4	336
249	All-trans Retinoic Acid in Association with Low Dose Cytosine Arabinoside in the Treatment of Acute Myeloid Leukemia in Elderly Patients. <i>American Journal of Therapeutics</i> , 2007, 14, 351-355.	0.9	18
250	Therapy-related leukemia and myelodysplasia: susceptibility and incidence. <i>Haematologica</i> , 2007, 92, 1389-1398.	3.5	184
251	Posttransplant Lymphoproliferative Disorders After Liver Transplantation: Analysis of Early and Late Cases in a 255 Patient Series. <i>Transplantation Proceedings</i> , 2007, 39, 1956-1960.	0.6	25
252	Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. <i>Annals of Oncology</i> , 2007, 18, 1523-1528.	1.2	61

#	ARTICLE	IF	CITATIONS
253	The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. <i>Oncogene</i> , 2007, 26, 3679-3690.	5.9	79
254	Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. <i>Annals of Hematology</i> , 2007, 86, 225-226.	1.8	23
255	Gemtuzumab-Ozogamicin, Cytosine Arabinoside, G-CSF Combination (G-AraMy) in the Treatment of Secondary Acute Myeloid Leukemia in Elderly Patients.. <i>Blood</i> , 2007, 110, 4377-4377.	1.4	0
256	451 High prevalence of hepatitis B virus infection in b-cell non-hodgkin lymphoma. <i>Journal of Hepatology</i> , 2006, 44, S168.	3.7	1
257	Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2006, 4, 33-52.	1.0	12
258	Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. <i>Experimental Hematology</i> , 2006, 34, 54-65.	0.4	25
259	Fungal Pneumonia Due to Molds in Patients with Hematological Malignancies. <i>Journal of Chemotherapy</i> , 2006, 18, 339-352.	1.5	17
260	NK/T-cell lymphomas â€˜nasal typeâ€™: an Italian multicentric retrospective survey. <i>Annals of Oncology</i> , 2006, 17, 794-800.	1.2	69
261	Acute lymphoblastic leukemia in elderly patients: clinical characteristics, treatment and outcome. <i>Aging Health</i> , 2006, 2, 123-133.	0.3	0
262	High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. <i>Haematologica</i> , 2006, 91, 554-7.	3.5	106
263	The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. <i>Haematologica</i> , 2006, 91, 1068-75.	3.5	650
264	The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1985-1992.	3.8	206
265	Gemcitabine as frontline treatment for cutaneous Tâ€‘cell lymphoma. <i>Cancer</i> , 2005, 104, 2437-2441.	4.1	149
266	Repeated Sequences in CASPASE-5 and FANCD2 but not NF1 Are Targets for Mutation in Microsatellite-Unstable Acute Leukemia/Myelodysplastic Syndrome. <i>Molecular Cancer Research</i> , 2005, 3, 251-260.	3.4	23
267	Breakthrough Zygomycosis and Voriconazole. <i>Journal of Infectious Diseases</i> , 2005, 192, 1496-1497.	4.0	18
268	Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. <i>Annals of Oncology</i> , 2005, 16, 228-233.	1.2	24
269	Treatment of Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 926-927.	1.6	11
270	Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. <i>Annals of Medicine</i> , 2005, 37, 259-269.	3.8	25

#	ARTICLE	IF	CITATIONS
271	Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1818-1828.	3.9	347
272	Fungal CNS infections in patients with hematologic malignancy. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 775-785.	4.4	42
273	Gentuzumab-Ozogamicin, Cytosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.. <i>Blood</i> , 2005, 106, 4604-4604.	1.4	1
274	Epidemiology of Fungal Infections in Hematological Malignancies in Italy: SEIFEM-2004 Study (Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne).. <i>Blood</i> , 2005, 106, 4556-4556.	1.4	1
275	AML-M4: Role of Eosinophilia and Cytogenetics on Treatment Response and Survival. The GIMEMA Experience.. <i>Blood</i> , 2005, 106, 4501-4501.	1.4	0
276	The Treatment of Acute Lymphoblastic Leukaemia in the Elderly. <i>Leukemia and Lymphoma</i> , 2004, 45, 117-123.	1.3	18
277	Aspergillus niger infection in patients with haematological diseases: a report of eight cases. Fallbericht. Aspergillus niger-Infektionen bei Patienten mit hamatologischen Erkrankungen. <i>Mycoses</i> , 2004, 47, 163-167.	4.0	25
278	Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. <i>Leukemia</i> , 2004, 18, 651-653.	7.2	3
279	Toxoplasma gondii infection in patients with hematological malignancies. <i>Annals of Hematology</i> , 2004, 83, 592-595.	1.8	25
280	Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic catecholamine excess. A case report in a young girl with recurrent, functioning paraganglioma. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 774-777.	3.3	1
281	Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. <i>Blood</i> , 2004, 103, 698-700.	1.4	79
282	Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. <i>Haematologica</i> , 2004, 89, 70-6.	3.5	37
283	Mucormycosis in hematologic patients. <i>Haematologica</i> , 2004, 89, 207-14.	3.5	213
284	Survival of elderly patients with acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 296-302.	3.5	43
285	In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gentuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. <i>Haematologica</i> , 2004, 89, 634-6.	3.5	16
286	Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 664-70.	3.5	46
287	Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. <i>Haematologica</i> , 2004, 89, 852-6.	3.5	27
288	Adenovirus meningoencephalitis in a patient with large B-cell lymphoma. <i>Annals of Hematology</i> , 2003, 82, 313-315.	1.8	13

#	ARTICLE	IF	CITATIONS
289	Comparison of Real-Time PCR, Conventional PCR, and Galactomannan Antigen Detection by Enzyme-Linked Immunosorbent Assay Using Bronchoalveolar Lavage Fluid Samples from Hematology Patients for Diagnosis of Invasive Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3922-3925.	3.9	134
290	Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. <i>DNA Repair</i> , 2003, 2, 547-559.	2.8	45
291	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1441-1443.	1.3	7
292	Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 211-214.	3.6	12
293	Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome after bupropion treatment for smoking cessation. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 77-78.	1.0	3
294	Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. <i>Haematologica</i> , 2003, 88, 223-5.	3.5	28
295	Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo AML. <i>Haematologica</i> , 2003, 88, 225-7.	3.5	4
296	Characteristics of Secondary Acute Lymphoblastic Leukemia with L3 Morphology in Adult Patients. <i>Leukemia and Lymphoma</i> , 2002, 43, 1599-1604.	1.3	3
297	Invasive Fungal Infection in Patients with Myelodysplastic Syndrome: A Report of Twelve Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 1613-1617.	1.3	5
298	Successful Treatment with Caspofungin of Hepatosplenic Candidiasis Resistant to Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2002, 35, 1135-1136.	5.8	41
299	Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	1.4	110
300	Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. <i>Blood</i> , 2002, 100, 1972-1976.	1.4	91
301	Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. <i>Blood</i> , 2002, 100, 1514-1515.	1.4	5
302	Filamentous Fungi Infection in Patients with Myelodysplastic Syndrome. A Report of Twelve Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 1421-1425.	1.3	1
303	<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. <i>British Journal of Haematology</i> , 2002, 117, 379-386.	2.5	123
304	Acute megakaryoblastic leukemia: experience of GIMEMA trials. <i>Leukemia</i> , 2002, 16, 1622-1626.	7.2	81
305	Simultaneous presentation of Waldenstrom's macroglobulinemia and acute myeloid leukemia. <i>Haematologica</i> , 2002, 87, EIM07.	3.5	0
306	Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. <i>Haematologica</i> , 2002, 87, 535-41.	3.5	64

#	ARTICLE	IF	CITATIONS
307	Use of gemcitabine (GEM) in advanced myelodysplastic syndromes. <i>Annals of Oncology</i> , 2001, 12, 1494.	1.2	2
308	Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group. <i>Annals of Oncology</i> , 2001, 12, 203-208.	1.2	20
309	Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. <i>British Journal of Haematology</i> , 2001, 112, 109-117.	2.5	51
310	Case Reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy. <i>Mycoses</i> , 2001, 44, 201-203.	4.0	6
311	Therapy Related Leukemias: Susceptibility, Prevention and Treatment. <i>Leukemia and Lymphoma</i> , 2001, 41, 255-276.	1.3	115
312	IDENTIFICATION OF Hb VILLEJUIF [$\beta^{123}(H1)Thr\alpha^1Ile$] IN SOUTHERN ITALY. <i>Hemoglobin</i> , 2001, 25, 67-78.	0.8	1
313	Fluconazole and <i>Candida krusei</i> Fungemia. <i>Archives of Internal Medicine</i> , 2001, 161, 2267-2269.	3.8	8
314	The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia. <i>Haematologica</i> , 2001, 86, 440-1.	3.5	4
315	Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. <i>Haematologica</i> , 2001, 86, 862-70.	3.5	107
316	Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia The gimema experience. <i>Experimental Hematology</i> , 2000, 28, 1501-1502.	0.4	4
317	Tunneling Schmorl's nodes in an elderly woman treated for acute lymphoblastic leukemia. <i>Skeletal Radiology</i> , 2000, 29, 660-663.	2.0	4
318	Cutaneous Aspergillosis in Patients with Haematological Malignancies. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000, 19, 362-365.	2.9	53
319	Clinical and Epidemiological Features of Acute Lymphoblastic Leukemia Following a Previous Malignancy. <i>Leukemia and Lymphoma</i> , 2000, 39, 465-475.	1.3	22
320	Chemotherapy of Secondary Leukemias. <i>Leukemia and Lymphoma</i> , 2000, 37, 543-549.	1.3	8
321	Acute leukemia following a previous malignancy: do acute lymphoid leukemia and acute myeloid leukemia have common risk factors?. <i>The Hematology Journal</i> , 2000, 1, 329-332.	1.4	8
322	Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. <i>British Journal of Haematology</i> , 2000, 111, 334-337.	2.5	16
323	The epidemiology of fusariosis in patients with haematological diseases. <i>British Journal of Haematology</i> , 2000, 111, 272-276.	2.5	59
324	Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkin's lymphoma A case report and review of literature. <i>Haematologica</i> , 2000, 85, 544-8.	3.5	9

#	ARTICLE	IF	CITATIONS
325	Isolated primary Hodgkin's disease of rectum. <i>Haematologica</i> , 2000, 85, 986-7.	3.5	3
326	Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. <i>Haematologica</i> , 2000, 85, 1327-9.	3.5	30
327	Itraconazole Oral Solution as Prophylaxis for Fungal Infections in Neutropenic Patients with Hematologic Malignancies: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. <i>Clinical Infectious Diseases</i> , 1999, 28, 250-255.	5.8	233
328	Idarubicin including regimens in acute myelogenous leukemia in elderly patients. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 59-68.	4.4	7
329	Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA Archive of Adult Acute Leukaemia. <i>British Journal of Haematology</i> , 1999, 106, 1037-1040.	2.5	70
330	Hb rainier [$\beta^{145}(\text{HC}2)\text{Tyr}\rightarrow\text{Cys}$] in Italy. Characterization of the amino acid substitution and the DNA mutation. <i>Hemoglobin</i> , 1999, 23, 111-124.	0.8	11
331	Oral ipriflavone (7-isopropoxyisoflavone) treatment for elderly patients with resistant acute leukemias. <i>Annals of Oncology</i> , 1999, 10, 124-125.	1.2	11
332	Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. <i>European Journal of Haematology</i> , 1999, 63, 77-85.	2.2	71
333	PCR-Restriction Enzyme Analysis for Detection of Candida DNA in Blood from Febrile Patients with Hematological Malignancies. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1871-1875.	3.9	88
334	Acute hemorrhagic leukoencephalitis in patients with acute myeloid leukemia in hematologic complete remission. <i>Haematologica</i> , 1999, 84, 270-4.	3.5	5
335	The incidence of secondary leukemias. <i>Haematologica</i> , 1999, 84, 937-45.	3.5	207
336	Atypical Sweet's syndrome in a neutropenic patient with acute myeloid leukemia, secondary to a RAEB-T, simulating thrombophlebitis. <i>Panminerva Medica</i> , 1999, 41, 261-3.	0.8	2
337	An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. <i>Journal of Infection</i> , 1998, 37, 173-180.	3.3	250
338	The effect of increased weight on peak pressures: Implications for obesity and diabetic foot pathology. <i>Journal of Foot and Ankle Surgery</i> , 1998, 37, 416-420.	1.0	75
339	Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukaemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. <i>British Journal of Haematology</i> , 1998, 100, 669-676.	2.5	12
340	Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia. <i>European Journal of Haematology</i> , 1998, 61, 327-332.	2.2	21
341	Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haematological malignancies: a problem of increasing importance. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 738-740.	3.0	18
342	Extramedullary Relapse in Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1997, 26, 417-418.	1.3	3

#	ARTICLE	IF	CITATIONS
343	The Role of Bronchoalveolar Lavage in the Microbiological Diagnosis of Pneumonia in Patients with Haematological Malignancies. <i>Annals of Medicine</i> , 1997, 29, 535-540.	3.8	29
344	The formation of bubbles in Zr alloys under Kr ion irradiation. <i>Journal of Nuclear Materials</i> , 1997, 244, 295-304.	2.7	24
345	Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. <i>Journal of Infection</i> , 1997, 34, 55-60.	3.3	23
346	Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. <i>British Journal of Haematology</i> , 1997, 99, 331-336.	2.5	192
347	Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. <i>Haematologica</i> , 1997, 82, 415-9.	3.5	39
348	Prognostic Relevance of Lipoprotein Cholesterol Levels in Acute Lymphocytic and Nonlymphocytic Leukemia. <i>Acta Haematologica</i> , 1996, 96, 24-28.	1.4	23
349	Adjuvant therapy with rhGM-CSF for the treatment of <i>Blastoschizomyces capitatus</i> systemic infection in a patient with acute myeloid leukemia. <i>Annals of Hematology</i> , 1996, 73, 33-34.	1.8	24
350	Localization of Aspergillosis to the Central Nervous System Among Patients with Acute Leukemia: Report of 14 Cases. <i>Clinical Infectious Diseases</i> , 1996, 23, 628-630.	5.8	55
351	Aprotinin employment in patients with acute leukaemia to prevent haemorrhage during pulmonary aspergillosis. <i>British Journal of Haematology</i> , 1996, 94, 210-1.	2.5	2
352	Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. <i>Haematologica</i> , 1996, 81, 343-45.	3.5	24
353	Intrathecal chemotherapy for treatment of overt meningeal leukemia: Comparison between intraventricular and traditional intralumbar route. <i>Annals of Oncology</i> , 1995, 6, 377-382.	1.2	25
354	Fatal haemoptysis in pulmonary filamentous mycosis: an undervalued cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. <i>British Journal of Haematology</i> , 1995, 89, 500-505.	2.5	89
355	<i>In vitro</i> susceptibility of <i>Candida</i> species isolated from patients with haematological malignancies. <i>Mycoses</i> , 1995, 38, 59-67.	4.0	5
356	Role of <i>Pneumocystis carinii</i> ; DNA Amplification by PCR on the Diagnosis of <i>Pneumocystis carinii</i> ; <i>Pneumonia</i> in Patients with Haematologic Malignant Diseases: Report of Four Cases. <i>Acta Haematologica</i> , 1995, 94, 163-166.	1.4	3
357	Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program. <i>Antimicrobial Agents and Chemotherapy</i> , 1994, 38, 2041-2046.	3.2	76
358	Acute parotitis during induction therapy including l-asparaginase in acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 1994, 68, 91-92.	1.8	8
359	Prevalence of obesity in young adults with acute lymphoblastic leukemia. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 117-119.	1.0	5
360	Lipids and lipoproteins in acute lymphoblastic leukaemia (ALL). <i>Leukemia Research</i> , 1994, 18, 643-644.	0.8	21

#	ARTICLE	IF	CITATIONS
361	Preventing Fungal Infection in Neutropenic Patients with Acute Leukemia: Fluconazole Compared with Oral Amphotericin B. <i>Annals of Internal Medicine</i> , 1994, 120, 913.	3.9	130
362	Pulmonary aspergillosis in patients with hematologic malignancies: clinicroadiologic correlation. <i>Rays</i> , 1994, 19, 465-78.	0.2	1
363	Myelo- and lymphoproliferative disorders: evaluation of hepatosplenic infiltrates and role of US-CT-guided aspiration biopsy. <i>Rays</i> , 1994, 19, 479-89.	0.2	0
364	Salvage chemotherapy with pentostatin in prolymphocytic leukemia. <i>Haematologica</i> , 1994, 79, 542-5.	3.5	0
365	The yield of bronchoalveolar lavage in the etiological diagnosis of pneumonia in leukemia and lymphoma patients. <i>European Journal of Haematology</i> , 1993, 51, 256-258.	2.2	18
366	Granuloblastic masses in the breast: report of two cases. <i>Haematologia</i> , 1993, 25, 287-91.	0.3	3
367	Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. <i>Leukemia</i> , 1993, 7, 196-9.	7.2	44
368	Recovery from diabetes insipidus associated with AML after a BMT conditioning regimen including busulfan. <i>Bone Marrow Transplantation</i> , 1993, 11, 175-6.	2.4	8
369	Hepato-Splenic Mycotic Abscesses in Patients with Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 7, 517-519.	1.3	1
370	A Leukemic Patient with Hepatosplenic Abscesses Due to Coagulase-Negative Staphylococci. <i>Clinical Infectious Diseases</i> , 1992, 14, 364-365.	5.8	8
371	Aggressive Chemotherapy for Acute Leukemia Relapsed after Bone Marrow Transplantation: A Second Chance?. <i>Acta Haematologica</i> , 1992, 87, 173-175.	1.4	2
372	Apparent Isolated Skin Relapse in Acute Monocytic Leukemia. A Case Report. <i>Tumori</i> , 1991, 77, 172-174.	1.1	2
373	Sequential Fibrinolytic Treatment with Urokinase and rt-TPA in two Cases of Acute Arterial Thromboembolism—Case Reports. <i>Vascular Surgery</i> , 1991, 25, 289-294.	0.3	1
374	Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients. <i>Haematologica</i> , 1991, 76, 517-8.	3.5	9
375	Gastrointestinal cancer in patients with chronic myeloid leukemia on busulphan treatment. <i>American Journal of Hematology</i> , 1990, 35, 69-69.	4.1	2
376	Acute Nonlymphoblastic Leukemia: Treatment of Elderly Patients. <i>Leukemia and Lymphoma</i> , 1990, 2, 243-245.	1.3	0
377	Iron chelation in rheumatoid arthritis: clinical and laboratory evaluation.. <i>Annals of the Rheumatic Diseases</i> , 1990, 49, 268-269.	0.9	8
378	Cystic fibrosis complicated by Hodgkin's lymphoma. <i>Panminerva Medica</i> , 1990, 32, 149-50.	0.8	2

#	ARTICLE	IF	CITATIONS
379	Liquoral myelin basic protein in acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 1989, 42, 407-8.	2.2	0
380	Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia. <i>Haematologica</i> , 1989, 74, 57-61.	3.5	8
381	Central nervous system acute promyelocytic leukaemia: a report of three cases. <i>Haematologia</i> , 1989, 22, 195-9.	0.3	13
382	An evaluation of some inflammatory, coagulative and immune factors in progressive systemic sclerosis. <i>Panminerva Medica</i> , 1989, 31, 76-9.	0.8	1
383	Evaluation of some inflammatory, coagulative and immune parameters in progressive systemic sclerosis. <i>Acta Medica Polona</i> , 1988, 29, 81-8.	0.0	0
384	Emergency abdominal surgery in patients with acute leukemia and lymphoma. <i>The Italian Journal of Surgical Sciences</i> , 1988, 18, 361-3.	0.0	6
385	Serum lactate dehydrogenase isoenzyme pattern in non-Hodgkin's lymphomas. <i>International Journal of Biological Markers</i> , 1988, 3, 237-42.	1.8	1
386	Serum beta 2 microglobulin in psoriasis and psoriatic patients. <i>Klinische Wochenschrift</i> , 1987, 65, 341-341.	0.6	1
387	β ² -Thalassaemia in Campania: DNA polymorphism analysis in β ² A and β ² that chromosomes and its usefulness in prenatal diagnosis. <i>British Journal of Haematology</i> , 1987, 67, 231-234.	2.5	18
388	AGGRESSIVE CHEMOTHERAPY IN THE TREATMENT OF SUBACUTE MYELOMONOCYTIC LEUKAEMIA WITH SKIN INFILTRATION. <i>British Journal of Haematology</i> , 1987, 67, 246-247.	2.5	3
389	Spinal fluid procoagulant activity in leukaemic patients treated with intrathecal methotrexate. <i>Haematologia</i> , 1987, 20, 41-7.	0.3	2
390	Cerebrospinal fluid protein findings during prophylaxis and treatment of neuromeningitis in leukaemic patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1987, 47, 765-9.	1.2	0
391	Antithrombin III in full-term and pre-term newborn infants: three cases of neonatal diagnosis of AT III congenital defect. <i>Thrombosis and Haemostasis</i> , 1987, 57, 329-31.	3.4	1
392	OKT4/OKT8 ratio and serum beta 2-microglobulin in mycosis fungoides and chronic benign dermatitis. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 663-669.	0.7	2
393	Antithrombin III during High-Dose Cytosine Arabinoside Therapy with or without Asparaginase. <i>Acta Haematologica</i> , 1986, 75, 96-99.	1.4	8
394	Ovarian Granulocytic Sarcoma with Central Nervous System Involvement. <i>Tumori</i> , 1986, 72, 335-338.	1.1	1
395	Cerebrospinal fluid beta ² microglobulin: A reliable index of leukaemic infiltration of central nervous system. <i>European Journal of Haematology</i> , 1986, 37, 301-305.	2.2	5
396	6-MP, VCR, MTX, PDN combination (POMP) in refractory or relapsed anll. <i>Leukemia Research</i> , 1986, 10, 110.	0.8	0

#	ARTICLE	IF	CITATIONS
397	Beta-2-microglobulin and ferritin values in cerebrospinal fluid of patients with acute leukemia. <i>Haematologica</i> , 1986, 71, 109-12.	3.5	1
398	Solid leukemic intracerebral deposits in patients with acute leukemia. <i>Haematologica</i> , 1986, 71, 303-6.	3.5	2
399	Factor VIII complex in progressive systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 1986, 4, 319-21.	0.8	5
400	Cerebrospinal fluid beta-2-microglobulin level as marker of central nervous system involvement in lymphoma. <i>Haematologia</i> , 1986, 19, 121-5.	0.3	0
401	Antithrombin III in Acute Viral Hepatitis. <i>Acta Clinica Belgica</i> , 1985, 40, 236-239.	1.2	0
402	Serum β_2 -microglobulin in systemic sclerosis. <i>Clinical Rheumatology</i> , 1985, 4, 286-289.	2.2	4
403	Evaluation of some coagulation parameters in cerebral ischemia. <i>Acta Neurologica Scandinavica</i> , 1983, 67, 210-217.	2.1	17